1. Home
  2. MREO vs GCI Comparison

MREO vs GCI Comparison

Compare MREO & GCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MREO
  • GCI
  • Stock Information
  • Founded
  • MREO 2015
  • GCI 1997
  • Country
  • MREO United Kingdom
  • GCI United States
  • Employees
  • MREO N/A
  • GCI N/A
  • Industry
  • MREO Biotechnology: Pharmaceutical Preparations
  • GCI Newspapers/Magazines
  • Sector
  • MREO Health Care
  • GCI Consumer Discretionary
  • Exchange
  • MREO Nasdaq
  • GCI Nasdaq
  • Market Cap
  • MREO 438.8M
  • GCI 509.6M
  • IPO Year
  • MREO N/A
  • GCI N/A
  • Fundamental
  • Price
  • MREO $1.74
  • GCI $4.23
  • Analyst Decision
  • MREO Strong Buy
  • GCI Buy
  • Analyst Count
  • MREO 5
  • GCI 3
  • Target Price
  • MREO $7.20
  • GCI $5.70
  • AVG Volume (30 Days)
  • MREO 1.8M
  • GCI 2.0M
  • Earning Date
  • MREO 08-12-2025
  • GCI 07-31-2025
  • Dividend Yield
  • MREO N/A
  • GCI N/A
  • EPS Growth
  • MREO N/A
  • GCI N/A
  • EPS
  • MREO N/A
  • GCI 0.73
  • Revenue
  • MREO $500,000.00
  • GCI $2,390,148,000.00
  • Revenue This Year
  • MREO N/A
  • GCI N/A
  • Revenue Next Year
  • MREO $38.38
  • GCI N/A
  • P/E Ratio
  • MREO N/A
  • GCI $5.77
  • Revenue Growth
  • MREO N/A
  • GCI N/A
  • 52 Week Low
  • MREO $1.47
  • GCI $2.55
  • 52 Week High
  • MREO $5.02
  • GCI $5.93
  • Technical
  • Relative Strength Index (RSI)
  • MREO 44.98
  • GCI 62.14
  • Support Level
  • MREO $1.64
  • GCI $3.76
  • Resistance Level
  • MREO $1.78
  • GCI $4.34
  • Average True Range (ATR)
  • MREO 0.09
  • GCI 0.28
  • MACD
  • MREO 0.04
  • GCI 0.03
  • Stochastic Oscillator
  • MREO 87.10
  • GCI 85.53

About MREO Mereo BioPharma Group plc

Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

About GCI Gannett Co. Inc.

Gannett Co Inc is a digital newspaper company providing local media and marketing solutions in the U.S. The group operates in three segments, Domestic Gannett Media, Newsquest, and Digital Marketing Solutions. The majority of revenue is from the Domestic Gannett Media segment. The company's brands include USA TODAY and more than 250 daily newspapers as well as digital marketing services companies, including ReachLocal, WordStream, and others. The company produces more than 350 annual events, such as themed expos. The company also operates in the U.K. through the U.K. media company Newsquest, providing more than 150 local media brands.

Share on Social Networks: